STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir AB (Nasdaq Stockholm: MVIR) announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to 234 MUSD, of which 98 MUSD were sales in the USA.
Medivir’s royalties based on sales for the first quarter are calculated from the lowest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate. The royalty amounted to 129 MSEK (13.8 MEUR).
OLYSIO® global net sales Sales in MUSD Market Q1 -2015 Q1-2014 Change US 98 291 -66% RoW 136 63 116% Total global net sales MUSD 234 354 -34%
Medivir will publish its Financial Statement on May 5, 2015 at 10.00 CET followed by a conference call for investors, analysts and the media at 12.30 CET. More information about the conference call/webcast will be posted at www.medivir.com.
Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 14 April 2015.
About Simeprevir (OLYSIO®)
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen Sciences Ireland UC and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. In November 2013, simeprevir was approved by the U.S. Food & Drug Administration and, in May 2014, it was granted marketing authorisation by the European Commission. Subsequent marketing authorisations have followed in several other countries around the world. Indications vary by market.
Medivir (STO:MVIRB) is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com